- Home
- IVA vs ORIC Comparison
IVA vs ORIC Comparison
Compare IVA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- ORIC
- Stock Information
- Founded
- IVA 2011
- ORIC 2014
- Country
- IVA France
- ORIC United States
- Employees
- IVA N/A
- ORIC N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- ORIC Health Care
- Exchange
- IVA Nasdaq
- ORIC Nasdaq
- Market Cap
- IVA 359.6M
- ORIC 362.9M
- IPO Year
- IVA 2020
- ORIC 2020
- Fundamental
- Price
- IVA $3.09
- ORIC $10.21
- Analyst Decision
- IVA Strong Buy
- ORIC Strong Buy
- Analyst Count
- IVA 4
- ORIC 8
- Target Price
- IVA $10.50
- ORIC $18.83
- AVG Volume (30 Days)
- IVA 29.4K
- ORIC 1.2M
- Earning Date
- IVA 03-26-2025
- ORIC 08-11-2025
- Dividend Yield
- IVA N/A
- ORIC N/A
- EPS Growth
- IVA N/A
- ORIC N/A
- EPS
- IVA N/A
- ORIC N/A
- Revenue
- IVA $14,591,573.00
- ORIC N/A
- Revenue This Year
- IVA $15.38
- ORIC N/A
- Revenue Next Year
- IVA $24.22
- ORIC N/A
- P/E Ratio
- IVA N/A
- ORIC N/A
- Revenue Growth
- IVA N/A
- ORIC N/A
- 52 Week Low
- IVA $1.53
- ORIC $3.90
- 52 Week High
- IVA $4.05
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- IVA 41.87
- ORIC 63.99
- Support Level
- IVA $3.00
- ORIC $10.05
- Resistance Level
- IVA $3.40
- ORIC $10.99
- Average True Range (ATR)
- IVA 0.20
- ORIC 0.60
- MACD
- IVA -0.04
- ORIC -0.07
- Stochastic Oscillator
- IVA 12.28
- ORIC 54.67
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.